DERMATITIS, ATOPIC

This study tested an experimental drug called SCD-044 in 250 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo for 16 weeks. The main goal was to see if the drug could reduce eczema severity by at least 75%. This is a di…

This study looked at how dupilumab, a medication for moderate to severe eczema (atopic dermatitis), improves the skin's barrier function in Chinese patients. 44 participants received the drug for 16 weeks, and researchers measured water loss from the skin to see how well the barr…

This study tested a new medicine called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). The drug works by blocking a protein involved in inflammation. Participants received either 611 or a placebo, and researchers measured how much their skin improve…

This study tested a daily pill called abrocitinib for people aged 12 and older with moderate to severe eczema. It looked at how well the drug controls symptoms and its safety over a long period, up to 92 weeks or more. Participants had already completed an earlier study. The goal…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't helped enough by creams or other treatments. About 589 participants received either the study drug or a…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that didn't get better with creams or other treatments. The goal was to see if it could clear or nearly clear the skin and reduce eczem…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that didn't get better with creams. Participants also used standard steroid creams during the study. The goal was to see if the shot co…

This study tested a new drug called lunsekimig in 150 adults with moderate-to-severe eczema who did not get enough relief from topical treatments. Participants received one of three doses of the drug or a placebo as a shot under the skin for 24 weeks. The main goal was to see how…

This study looked at how dupilumab, a treatment for moderate-to-severe eczema, changes nerve fibers in the skin and reduces itching. 54 adults with chronic itch took part. Researchers took skin samples to measure nerve density and branching before and after treatment. The goal wa…

This study tested a new medication called BI 655130 in 51 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if it is safe and helps reduce skin symptoms like redness, itching, and thickening compared to a placebo. Participants received the drug or a p…

This early-stage study tested a new drug called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check the drug's safety and how the body processes it. Participants received a single dose of the drug or a placebo, and researchers mo…

This study tested the drug dupilumab in 41 children aged 6 to 12 with moderate to severe eczema (atopic dermatitis). The goal was to see if the drug improves the skin's barrier function by measuring how much water escapes through the skin. Researchers compared the children's skin…

This study looked at whether the eczema drug amlitelimab changes how well vaccines work in adults with moderate-to-severe atopic dermatitis. About 224 participants received either amlitelimab or a placebo along with two standard vaccines (tetanus/diphtheria/pertussis and pneumoni…

This study looked at how a new medicine called amlitelimab affects the way the body processes other drugs in adults with moderate-to-severe atopic dermatitis (eczema). 23 participants took part. The goal was to understand potential drug interactions to ensure safe use with other …